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The treatment of neuropsychiatric disorders currently relies on over 100 compounds but it is still far 
from being satisfactory regarding tolerability and, even more, efficacy given the high rate of partial or 
no benefit at all particularly in Schizophrenia and Alzheimer Disease. In fact, after over 50 years from 
the discovery of the first antidepressant and antipsychotic drugs, their mechanism of action still 
mainly relies upon the modulation of dopaminergic and serotonergic systems for psychiatric 
disorders and of acetylcholine for cognition. The benefits of these classes of compounds should not 
be underestimated but neither should their shortcomings, the number of patients that do not 
respond, nor the areas of clinical unmet need that current therapies do not even attempt to tackle.  
Few new mechanisms of action have been identified in the last decades. Paralleling, this innovative 
deceleration in the identification of novel therapeutic approaches our diagnostic framework has also 
only gone through a limited evolution over this same time-period.  Despite many significant advances, 
in quantitative neuroscience, clinical practice is still based principally on a qualitative assessment of 
perceived symptoms. It is clear therefore that we need a paradigm shift to rekindle the drug 
discovery process and facilitate better matching of patient to therapeutic. A number of projects have 
been recently proposed in order to innovate the field (see for example NEWMEDS (Artigas et al., 
2017)), but converging evidence, summarized in the first paper (Kas et al in this issue (Kas et al., 
2017)) suggests the need for a more radical change of perspective. The core of this thesis is that the 
direction for innovation should focus on the biological systems that can be quantitatively 
demonstrated as being altered in disease.  From this understanding new transdiagnostic hypotheses 
explaining the clinical deficits, independent from traditional categorical designations (O’Donnell and 
Ehlers, 2015) can be allowed to emerge. 
Having relied entirely on a clustered symptomatic classification of neuropsychiatric illness there is 
much discussion currently, such as the RDoC (Cuthbert, 2018) and ROAMER initiative (Haro et al., 
2014), as to whether a more pragmatic quantitative biology approach may now be achievable. 
Converging evidence is in fact suggesting that we are close to the point of achieving this goal.  As a 
consequence the transdiagnostic approach is gaining adherents in many areas and hence triggering 
novel experimental proposals (Bipolar Disorder and Schizophrenia Working Group of the Psychiatric 
Genomics Consortium., 2018)(Kas et al., 2007). Amongst these an industry consortium came together 
in 2014 and working through the Innovative Medicine Initiative (IMI) developed a call based on the 
emergence of the much improved ability to integrate imaging, electrophysiological, cognitive, genetic 
and real world parameters. This advent being viewed as an opportunity to bring a quantitative 
biological approach to the classification and understanding of this complex area. In particular, the call 
looked to determine whether similar symptomatologies, that are assumed to result from different 
pathological processes, could be dissociated using quantitative parameters. The identification of 
homogeneous subgroups of subjects sharing similar pathophysiological mechanisms may then 
facilitate; the discovery of innovative treatments, offer improved stratification of patients providing 
improved alignment of the best drug in the right patient as well as more rational clinical trial design, 
and in turn influence also regulatory processes (Tome and Isaac, 2018). From an academic 
perspective a biologically based clinical understand also offers dramatic improvements in our ability 
to reverse translate effectively into the pre-clinical milieu.    
The PRISM project (Psychiatric Ratings using Intermediate Stratified Markers), which developed from 
this call, has taken the theme of Social Withdrawal as the symptomatic dimension while 
schizophrenia and Alzheimer’s dementia provide the two differing pathologies which share this 
deleterious symptomatic dimension (https://prism-project.eu). In view of this symptomatic 
dimension, William Carpenter has provided a commentary manuscript for this special issue focusing 
on clinical concepts and the relevance of social engagement in psychopathology (Carpenter, 2017). 
The PRISM project aims to provide new classification tools focusing on the two main neuropsychiatric 
disorders based on quantitative biological parameters. This will be based on a deep phenotyping 
assessment in newly recruited subjects covering social withdrawal, attention, sensory processing, 
and working memory versus digital, brain imaging, EEG and epigenetic biomarkers. In addition, a 
cross-disorder genome-wide genetic analysis will be performed in the largest worldwide available 
cohorts of patients with the aim to identify shared genetic factors related to the common social 
withdrawal symptoms in these disorders. Furthermore, a preclinical platform will be implemented to 
allow back translation from human findings into rodents to facilitate studies to further our 
understanding of neurobiological substrates underlying the identified clinical and biologically 
meaningful quantitative parameters. For example, as was addressed by Hornix et al in this issue, 
studies on the combined analyses of neural circuit development and functioning will become 
necessary to expand our understanding of sensory processing and behavioural deficits that are 
relevant across the neuropsychiatric spectrum (Hornix et al., 2018). 
The manuscripts presented in this special issue review the pertinent literature and detail the concept 
from a variety of perspectives. The first paper (Kas et al in this issue (Kas et al., 2017)) addresses the 
background to the arguments in favour of a quantitative as opposed to a purely symptomatic 
approach in this area, the potential benefits if successful, and a broad brush outline as to how it is 
planned to achieve this goal.  Specifically, this involved identifying, what turned out to be, four key 
areas for analysis. Porcelli and colleagues (Porcelli et al., 2018) then lay out a comprehensive account 
of the current understanding of the neurobiology of social withdrawal that provides the foundation 
for the rest of the project. The innovative nature of this review is to combine existing evidence about 
neurobiology of social withdrawal in a way that makes clear how its determinants are, at least in 
part, independent from the clinical diagnosis of the subject. Moreover, determinants have been 
studied in previous human and animal studies but never combined in a unitary interrelated 
mechanism of action, which is presented in the paper. This model will constitute the working 
hypothesis to be tested within the project.  From these starting points the structure of the clinical 
recruitment work was devised based upon an assessment of the four key areas of research within the 
clinical study protocol (Bilderbeck in this issue (Bilderbeck et al., 2018)).  These four key areas are: 
social withdrawal itself (Van der Wee, et al in this issue (van der Wee et al., 2018)), sensory 
processing (Danjou, et al in this issue (Danjou et al., 2018)), as well as attention and working memory 
(Gilmour, et al in this issue[MK1]) identified by the teams initial review. Furthermore, the potential for 
back translation of human findings using homologous paradigms in rodents is then reviewed in detail 
(Hengerer in this issue[MK2]).  These areas also share the key attribute that we believe they are robust 
and deliverable within the practical constraints of the resources available to the project. There are 
though other areas that have transdiagnostic relevance in this area.  A good example of this are sleep 
disturbances. In this issue Winsky-Sommerer et al aware of the PRISM initiative have taken this 
transdiagnostic perspective to review whether sleep; its quality, timing and structure, could be 
another rich vein to explore if certainly technical challenges can be addressed (Winsky-Sommerer et 
al., 2018). 
The material included in this issue it is hoped will therefore inform the reader about the background 
and evidence of a potentially fruitful improvement in the understanding of neuropsychiatric 
disorders based on quantitative biological parameters possibly leading to more effective clinical and 
pre-clinical research and drug discovery. Further, should this approach prove fruitful our need to 
review the literature across traditional classifications will become vital.  These reviews may therefore 
provide a template for this novel perspective while also retaining a pragmatic realism derived from 
the technical challenges of such transdiagnostic approaches.   
 
References  
Artigas, F., Schenker, E., Celada, P., Spedding, M., Lladó-Pelfort, L., Jurado, N., Núñez, M., Santana, N., 
Troyano-Rodriguez, E., Riga, M.S., van den Munkhof, H., Castañé, A., Shaban, H., Jay, T.M., 
Tripathi, A., Godsil, B.P., Sebban, C., Mariani, J., Faure, P., Takkilah, S., Hughes, Z.A., Siok, C.J., 
Hajos, M., Wicke, K., Gass, N., Weber-Fahr, W., Sartorius, A., Becker, R., Didriksen, M., Bastlund, 
J.F., Tricklebank, M., Risterucci, C., Meyer-Lindenberg, A., Schwarz, A.J., 2017. Defining the brain 
circuits involved in psychiatric disorders: IMI-NEWMEDS. Nat. Rev. Drug Discov. 16, 1–2. 
doi:10.1038/nrd.2016.205 
Bilderbeck, A.C., Penninx, B.W.J.H., Arango, C., van der Wee, N., Kahn, R., Winter-van Rossum, I., 
Hayen, A., Kas, M.J., Post, A., Dawson, G.R., 2018. Overview of the clinical implementation of a 
study exploring social withdrawal in patients with schizophrenia and Alzheimer’s disease. 
Neurosci. Biobehav. Rev. doi:10.1016/j.neubiorev.2018.06.019 
Bipolar Disorder and Schizophrenia Working Group of the Psychiatric Genomics Consortium., 2018. 
Genomic Dissection of Bipolar Disorder and Schizophrenia, Including 28 Subphenotypes. Cell 
173, 1705–1715.e16. doi:10.1016/j.cell.2018.05.046 
Carpenter, W.T., 2017. Social withdrawal as psychopathology of mental disorders. Neurosci. 
Biobehav. Rev. doi:10.1016/j.neubiorev.2017.12.011 
Cuthbert, B.N., 2018. The PRISM Project: Social Withdrawal from an RDoC Perspective. Neurosci. 
Biobehav. Rev. doi:10.1016/j.neubiorev.2018.08.006 
Danjou, P., Viardot, G., Maurice, D., Garcés, P., Wams, E.J., Phillips, K.G., Bertaina-Anglade, V., 
McCarthy, A.P., Pemberton, D.J., 2018. Electrophysiological Assessment Methodology of 
Sensory Processing Dysfunction in Schizophrenia and Dementia of the Alzheimer Type. 
Neurosci. Biobehav. Rev. doi:10.1016/j.neubiorev.2018.09.004 
Haro, J.M., Ayuso-Mateos, J.L., Bitter, I., Demotes-Mainard, J., Leboyer, M., Lewis, S.W., Linszen, D., 
Maj, M., Mcdaid, D., Meyer-Lindenberg, A., Robbins, T.W., Schumann, G., Thornicroft, G., Van 
Der Feltz-Cornelis, C., Van Os, J., Wahlbeck, K., Wittchen, H.-U., Wykes, T., Arango, C., 
Bickenbach, J., Brunn, M., Cammarata, P., Chevreul, K., Evans-Lacko, S., Finocchiaro, C., Fiorillo, 
A., Forsman, A.K., Hazo, J.-B., Knappe, S., Kuepper, R., Luciano, M., Miret, M., Obradors-Tarragó, 
C., Pagano, G., Papp, S., Walker-Tilley, T., 2014. ROAMER: roadmap for mental health research 
in Europe. Int. J. Methods Psychiatr. Res. 23, 1–14. doi:10.1002/mpr.1406 
Hornix, B.E., Havekes, R., Kas, M.J.H., 2018. Multisensory cortical processing and dysfunction across 
the neuropsychiatric spectrum. Neurosci. Biobehav. Rev. doi:10.1016/j.neubiorev.2018.02.010 
Kas, M.J., Penninx, B., Sommer, B., Serretti, A., Arango, C., Marston, H., 2017. A quantitative 
approach to neuropsychiatry: The why and the how. Neurosci. Biobehav. Rev. 
doi:10.1016/j.neubiorev.2017.12.008 
Kas, M.J.H., Fernandes, C., Schalkwyk, L.C., Collier, D.A., 2007. Genetics of behavioural domains 
across the neuropsychiatric spectrum; of mice and men. Mol. Psychiatry 12, 324–330. 
doi:10.1038/sj.mp.4001979 
O’Donnell, P., Ehlers, M.D., 2015. Opportunities for New Drug Development in Psychiatry: A Glass 
Half-Full. JAMA psychiatry 72, 1067–8. doi:10.1001/jamapsychiatry.2015.1735 
Porcelli, S., Van Der Wee, N., van der Werff, S., Aghajani, M., Glennon, J.C., van Heukelum, S., 
Mogavero, F., Lobo, A., Olivera, F.J., Lobo, E., Posadas, M., Dukart, J., Kozak, R., Arce, E., Ikram, 
A., Vorstman, J., Bilderbeck, A., Saris, I., Kas, M.J., Serretti, A., 2018. Social brain, social 
dysfunction and social withdrawal. Neurosci. Biobehav. Rev. 
doi:10.1016/j.neubiorev.2018.09.012 
Tome, M.B., Isaac, M.T., 2018. A regulatory view on novel methodologies and context of use of 
biomarkers. Neurosci. Biobehav. Rev. doi:10.1016/j.neubiorev.2018.09.015 
van der Wee, N.J.A., Bilderbeck, A.C., Cabello, M., Ayuso-Mateos, J.L., Saris, I.M.J., Giltay, E.J., 
Penninx, B.W.J.H., Arango, C., Post, A., Porcelli, S., 2018. Working definitions, subjective and 
objective assessments and experimental paradigms in a study exploring social withdrawal in 
schizophrenia and Alzheimer’s disease. Neurosci. Biobehav. Rev. 
doi:10.1016/j.neubiorev.2018.06.020 
Winsky-Sommerer, R., de Oliveira, P., Loomis, S., Wafford, K., Dijk, D.-J., Gilmour, G., 2018. 
Disturbances of sleep quality, timing and structure and their relationship with other 
neuropsychiatric symptoms in Alzheimer’s disease and schizophrenia: insights from studies in 
patient populations and animal models. Neurosci. Biobehav. Rev. 
doi:10.1016/j.neubiorev.2018.09.027 
 
